Actionable news
0
All posts from Actionable news
Actionable news in VICL: Vical Incorporated,

RXi Pharmaceuticals to Present at the 15th Annual Biotech in Europe Forum for Global Partnering and Investment Conference

MARLBOROUGH, Mass., Sept. 15, 2015 /PRNewswire/ -- RXi Pharmaceuticals Corporation (RXII), a biotechnology company focused on discovering and developing innovative therapies primarily in the areas of dermatology and ophthalmology, today announced that Dr. Geert Cauwenbergh, RXi's President and CEO, will be participating in the upcoming 15th Annual Biotech in Europe Forum for Global Partnering and Investment Conference, with an oral presentation and panel discussion. This Forum is recognized as the leading international stage for those interested in investing and partnering in the biotech and life sciences industry.

Logo - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO

On Tuesday, September 29, 2015 from 12:00 to 1:00 p.m. CEST, Dr. Cauwenbergh will discuss the development and partnering strategy for RXi's proprietary self-delivering RNAi (sd-rxRNA®) platform during a panel discussion entitled Platform Technologies & Novel Therapeutics.

In addition, on that same day at 3:15 p.m. CEST, Dr. Cauwenbergh will present a corporate overview that includes multiple business development opportunities available based on RXi's proprietary sd-rxRNA® platform and extensive intellectual property portfolio. The presentation will be available on the Company's website at www.rxipharma.com approximately one hour after the presentation.

About the 15th Annual Biotech in Europe Forum

The Forum draws together an exciting cross-section of early-stage/pre-IPO, late-stage and public companies with leading investors, analysts, money managers and pharma licensing executives. This meeting is being held September 29-30, 2015 at the Congress Center in Basel, Switzerland.

About RXi Pharmaceuticals Corporation

RXi Pharmaceuticals Corporation (RXII) is a biotechnology company focused on discovering and developing innovative therapeutics primarily in the areas of dermatology and ophthalmology...


More